Whitehawk Therapeutics Inc. released a corporate presentation outlining its antibody-drug conjugate platform and a three-asset pipeline. The company highlighted a novel linker-payload approach featuring a topoisomerase 1 inhibitor payload with an optimized DAR6 configuration and cleavable linker design, as well as preclinical comparisons on potency, stability and safety measures. The presentation also summarized development plans for HWK-007 targeting PTK7, HWK-016 targeting MUC16, and HWK-206 targeting SEZ6, including expected Phase 1 indication areas and anticipated timing for initial data readouts for HWK-007 and HWK-016 in the first half of 2027, with an IND for HWK-206 expected by mid-2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.